John Schmid
Directeur/Bestuurslid bij XERIS BIOPHARMA HOLDINGS, INC.
Vermogen: 741 238 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Pratik Shah | M | 54 | 16 jaar | |
Beth Hecht | F | 60 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 9 jaar |
Mark Gergen | M | 61 | 6 jaar | |
Paul Edick | M | 67 | 7 jaar | |
Allison Wey | F | - |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | - |
Barbara-Jean Bormann-Kennedy | M | 65 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 6 jaar |
Kristin Yarema | M | 53 | 1 jaar | |
Dawn Halkuff | F | 53 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 6 jaar |
Eric Loumeau | M | 61 | 6 jaar | |
Jeffrey Sherman | M | 69 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 6 jaar |
Marla Persky | F | 68 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 6 jaar |
Daniel Faga | M | 44 | 3 jaar | |
Zachary A. Zimmerman | M | - |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | - |
Harry Leonhardt | M | 67 | 4 jaar | |
Johanna Mylet | F | 37 | 9 jaar | |
Charles Baum | M | 65 | 2 jaar | |
Mark Mckenna | M | 48 | - | |
Stella Xu | M | 53 | 4 jaar | |
Andrew Tomaras | M | - |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | 3 jaar |
Arsani William | M | 35 | 3 jaar | |
Luke Corning | M | 41 | 4 jaar | |
Kevin McCulloch | M | - |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 6 jaar |
Sarah Thailing | F | - | 4 jaar | |
Devon J. Shedlock | M | - | - | |
J. Ware | M | 71 | 7 jaar | |
Kristin Martin | F | 49 | 5 jaar | |
Ricki Fairley | F | 67 | 1 jaar | |
Heather Behanna | M | 49 | 3 jaar | |
Rodney Lappe | M | 69 | 5 jaar | |
Oleg Nodelman | M | 47 | 3 jaar | |
Marcea Lloyd | F | 75 | 5 jaar | |
Cynthia Collins | F | 65 | 3 jaar | |
John Johnson | M | 66 | 3 jaar | |
Hollings Renton | M | 77 | 9 jaar | |
Dennis Fenton | M | 72 | 6 jaar | |
Alex Zisson | M | 54 | 11 jaar | |
Garheng Kong | M | 49 | 3 jaar | |
Magda Marquet | M | 65 | 3 jaar | |
Simeon George | M | 46 | 4 jaar | |
David Puerta | M | - |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | - |
Loren Wagner | M | - | 3 jaar | |
Deepa Prasad | F | 44 | 3 jaar | |
Nick Montemarano | M | - | - | |
John Shannon | M | 62 | 3 jaar | |
Priya Raina | F | - | 2 jaar | |
Greg Pyszczymuka | M | - | 6 jaar | |
Lisa Portale | F | - | 5 jaar | |
Caleb Tripp | M | 38 | - | |
Ben Stone | M | - | 2 jaar | |
Dawn Giangiulio | F | - | 4 jaar | |
Stephen Worland | M | 66 |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | 7 jaar |
Steven Pieper | M | 47 | 3 jaar | |
Karen Basbaum | F | - | 4 jaar | |
Beth Mueller | F | - | 5 jaar | |
Ken Johnson | M | 61 | 3 jaar | |
Rita Jain | M | 61 | 1 jaar | |
David McKeon | M | 52 | 7 jaar | |
Brian Dorsey | M | 55 |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | 7 jaar |
Paul Lizzul | M | 49 | 4 jaar | |
Seth Cohen | M | - |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | - |
Monique da Silva | F | - | - | |
John Orwin | M | 62 | 1 jaar | |
Rafael Amado | M | 60 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Andreas Sommer | M | 83 | 6 jaar | |
Eric Ostertag | M | 51 | 9 jaar | |
Hamza Suria | M | 47 | 14 jaar | |
Vipin K. Garg | M | 67 | 5 jaar | |
Joao Siffert | M | 60 | 3 jaar | |
William Gerhart | M | - |
Patara Pharma LLC
Patara Pharma LLC Pharmaceuticals: MajorHealth Technology Patara Pharma LLC provides biotechnology solutions. It develops biopharmaceutical therapy for the treatment of allergic and inflammatory diseases and conditions that affect orphan patient populations. The company was founded by William Gerhart, Pravin Soni and Ahmet Tutuncu in 2013 and is headquartered in San Diego, CA. | 5 jaar |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 jaar |
Gerald McLaughlin | M | 56 | 3 jaar | |
Barry M. Deutsch | M | 61 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 4 jaar |
Carol Gallagher | M | 59 | 7 jaar | |
Richard Eisenstadt | M | 66 | 7 jaar | |
Brian E. Shanahan | M | 52 | - | |
Marco Londei | M | 68 | 6 jaar | |
Eun-Young Cha | M | 61 |
University of San Diego
| 3 jaar |
Donald Williams | M | 65 |
San Diego Venture Group
San Diego Venture Group Financial ConglomeratesFinance San Diego Venture Group operates as a non-profit organization that engages in the funding of start up companies. it focuses on the provision of support to the venture capital eco-system. It serves entrepreneurs, venture capitalists, community leaders, and business advisors. The company was founded in 1986 and is headquartered in San Diego, CA. | 13 jaar |
Justin Thacker | M | - | - | |
Nina Kjellson | F | 49 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Danielle Campbell | F | - | 5 jaar | |
Austin Kim | M | 60 | - | |
Alan L. Heller | M | 70 | 12 jaar | |
Russell McMahen | M | - | - | |
Paul Truex | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 jaar |
David Hirsch | M | 53 | 4 jaar | |
David Collier | M | 61 | 7 jaar | |
Mark Tengler | M | 56 | 7 jaar | |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 jaar |
James Topper | M | 62 | 16 jaar | |
Greg J. Robitaille | M | 60 | 12 jaar | |
Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Nancy T. Chang | M | 74 | 2 jaar | |
Karin Eastham | F | 74 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Samuel Saks | M | 69 | 6 jaar | |
Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Jonathan Rigby | M | 56 |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | 3 jaar |
Brian A. Lebrecht | M | - |
University of San Diego
| 8 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 97 | 97.98% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- John Schmid
- Persoonlijk netwerk